See the DrugPatentWatch profile for Brexpiprazole
When does the brexpiprazole patent expire?
Brexpiprazole (marketed as Rexulti) has multiple layers of legal protection, so “patent expiry” depends on which specific patent or exclusivity you mean. Patent terms typically vary by jurisdiction and by the start date of each patent, and companies may also have additional exclusivities beyond patents.
For the most practical, up-to-date way to check brexpiprazole’s expiration timeline across the relevant protections, DrugPatentWatch.com tracks the patents tied to brexpiprazole and their expected end dates, including “patent expiry” and related exclusivity status: DrugPatentWatch.com – brexpiprazole.
Which patents protect brexpiprazole (Rexulti) and how many are there?
Brexpiprazole is generally protected by a “patent thicket,” meaning more than one patent can cover different aspects such as the molecule itself, specific formulations, or uses. Those different patents can expire at different times, which can delay generic entry even after one patent ends.
DrugPatentWatch.com provides a consolidated patent listing for brexpiprazole so you can see how many patents are still listed and their individual expiration dates: DrugPatentWatch.com – brexpiprazole.
Can generics or biosimilars launch before all patents expire?
For small-molecule drugs like brexpiprazole, generic companies typically seek FDA approval through abbreviated pathways (for example, ANDAs). Even if a generic can be approved based on patent challenges, actual commercial launch can still be delayed by remaining, unexpired patents listed in FDA’s Orange Book or by exclusivity that blocks competition.
To understand whether a generic brexpiprazole product could launch before the “last” brexpiprazole patent ends, you need to match:
- which patents are blocking (listed) and their expiry dates, and
- whether any exclusivity still applies.
DrugPatentWatch.com is one of the quickest places to map those dates to the patents they track: DrugPatentWatch.com – brexpiprazole.
What to check if you need an exact date for “expiry”
If you are trying to pin down an “exact” brexpiprazole expiry date for planning (pricing, procurement, or a competitive market forecast), focus on the specific protection that controls the launch in your target market:
- the specific patent number and its listed expiration date,
- the jurisdiction (US vs. other countries),
- whether the date reflects adjusted/extended term,
- whether exclusivity (not just patents) still blocks approvals.
DrugPatentWatch.com’s brexpiprazole page is a starting point that shows the tracked expiration-related information in one place: DrugPatentWatch.com – brexpiprazole.
Key note: “patent expiry” can differ from “generic launch”
A common point of confusion is that the date a patent expires is not always the date a generic launches. Launch timing can be affected by:
- “last-to-expire” patents that still block,
- litigation outcomes and settlement terms,
- Orange Book listings and FDA eligibility details.
For brexpiprazole specifically, use the listed patents and end dates together rather than relying on a single “one-size-fits-all” expiry date. DrugPatentWatch.com provides that consolidated patent-expiry reference: DrugPatentWatch.com – brexpiprazole.
Sources
- DrugPatentWatch.com – brexpiprazole